Search company, investor...

Predict your next investment

Venture Capital
longitudecapital.com

Investments

138

Portfolio Exits

32

Funds

5

Service Providers

1

About Longitude Capital

Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. The Firm's growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile and attractive expected returns within three to five years from initial investment. Additionally, Longitude Capital utilizes a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity and equity-linked instruments.

Headquarters Location

800 El Camino Real Suite 220

Menlo Park, California, 94025,

United States

650-854-5700

Want to inform investors similar to Longitude Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Longitude Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Longitude Capital in 1 Expert Collection, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

Latest Longitude Capital News

CG Oncology secures $105m funds to advance bladder cancer programmes

Aug 3, 2023

Current investors Acorn Bioventures, Decheng Capital, Ally Bridge Group, Malin Corporation, RA Capital Management and Longitude Capital also took part in the round. CG Oncology plans to use the oversubscribed financing to progress clinical programmes in bladder cancer and obtain approval from the US Food and Drug Administration (FDA). The programmes include the single-arm, Phase III BOND-003 monotherapy clinical trial of cretostimogene grenadenorepvec. This could potentially treat patients with high-risk non-muscle invasive bladder cancer (NMIBC) not responsive to bacillus Calmette-Guerin (BCG). Cretostimogene grenadenorepvec is an oncolytic immunotherapy agent administered intravesically. It is being evaluated in a Phase II trial along with Keytruda (pembrolizumab) for the same indication. The agent is also being analysed along with Opdivo (nivolumab) for the treatment of other bladder cancer types. CG Oncology CEO Arthur Kuan stated: “We are excited to welcome leading life science investors who share our vision of developing cutting-edge therapeutics addressing unmet medical needs in bladder cancer. “Our lead asset, cretostimogene grenadenorepvec, continues to make significant clinical progress in bladder cancer in both monotherapy and combination studies. We are encouraged to see our treatments get closer to being available to bladder cancer patients worldwide.” Share this article

Longitude Capital Investments

138 Investments

Longitude Capital has made 138 investments. Their latest investment was in CG Oncology as part of their Series F on August 8, 2023.

CBI Logo

Longitude Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/2/2023

Series F

CG Oncology

$105M

No

4

5/24/2023

Seed VC

WKCGRG Holdings

$0.83M

Yes

1

4/17/2023

Series D

Cortica

$75M

No

4

2/20/2023

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/17/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/2/2023

5/24/2023

4/17/2023

2/20/2023

2/17/2023

Round

Series F

Seed VC

Series D

Series B

Series D

Company

CG Oncology

WKCGRG Holdings

Cortica

Subscribe to see more

Subscribe to see more

Amount

$105M

$0.83M

$75M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

1

4

10

10

Longitude Capital Portfolio Exits

32 Portfolio Exits

Longitude Capital has 32 portfolio exits. Their latest portfolio exit was AEON Biopharma on December 22, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/22/2022

Reverse Merger

$99M

3

12/21/2021

Acquired

$99M

10

10/7/2021

IPO

$99M

Public

11

7/30/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/16/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/22/2022

12/21/2021

10/7/2021

7/30/2021

7/16/2021

Exit

Reverse Merger

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

10

11

10

10

Longitude Capital Acquisitions

2 Acquisitions

Longitude Capital acquired 2 companies. Their latest acquisition was Ajax Vascular on November 26, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/26/2014

Series A

$99M

$1.5M

Asset Sale

8/20/2014

Debt

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/26/2014

8/20/2014

Investment Stage

Series A

Debt

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$1.5M

Note

Asset Sale

Subscribe to see more

Sources

10

Longitude Capital Fund History

5 Fund Histories

Longitude Capital has 5 funds, including Longitude Capital Prime Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/20/2021

Longitude Capital Prime Fund I

$135M

1

9/23/2020

Longitude Venture Partners IV

$99M

10

6/7/2016

Longitude Venture Partners III

Subscribe to see more

Subscribe to see more

$99M

10

10/22/2012

Longitude Venture Partners II

Subscribe to see more

Subscribe to see more

$99M

10

6/16/2008

Longitude Venture Partners

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/20/2021

9/23/2020

6/7/2016

10/22/2012

6/16/2008

Fund

Longitude Capital Prime Fund I

Longitude Venture Partners IV

Longitude Venture Partners III

Longitude Venture Partners II

Longitude Venture Partners

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$135M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Longitude Capital Service Providers

1 Service Provider

Longitude Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Longitude Capital Team

13 Team Members

Longitude Capital has 13 team members, including current Founder, Managing Director, Juliet Tammenoms Bakker.

Name

Work History

Title

Status

Juliet Tammenoms Bakker

Pequot Capital Mangement

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Juliet Tammenoms Bakker

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Pequot Capital Mangement

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.